This is a preview of subscription content, log in via an institution to check access.
Notes
rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
2013 euros
Reference
Sabater E, et al. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain. Applied Health Economics and Health Policy : 18 Apr 2016. Available from: URL: http://doi.org/10.1007/s40258-016-0243-4
Rights and permissions
About this article
Cite this article
First-line rituximab + bendamustine cost effective in advanced FL. PharmacoEcon Outcomes News 752, 16 (2016). https://doi.org/10.1007/s40274-016-3010-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3010-8